Spotlight On... Sun Pharma shedding Ohio plant with sale to Nostrum Laboratories; Walgreens picking up Valeant biz; Workers killed at India plant; Zimbabwe restarting pharma production; and more...

India's Sun Pharmaceutical, looking to cut back its manufacturing operations since its buyout of Ranbaxy Laboratories, will sell a formulation plant in Bryan, OH, to Nostrum Laboratories. The companies are keeping terms of the deal under wraps. Sun had picked the plant up in 2005 from Valeant Pharmaceuticals ($VRX). It is the second plant that Sun has indicated it will dispose of. In September, the company said it was looking at closing a plant in Tipperary, Ireland, with 100 employees. Release | More

> Walgreens Boots Alliance ($WBA) has reportedly won a deal to distribute products for the troubled Valeant Pharmaceuticals ($VRX) through which Valeant is said to be cutting prices by 10%. Story

> CDMO Ajinomoto Althea next month will begin offering antibody-drug conjugate (ADC) services at a new facility near its existing San Diego, CA, operations. Release

> The government of Zimbabwe has taken over and plans to restart CAPS Holdings, which was the country's largest drug manufacturer before it collapsed four years ago. Story

> Three workers were killed and two are in critical condition after reportedly inhaling poisonous gas while working on a tank at Shree Ganesh Remedies Company in Ankleshwar, India. Story

> U.S.-based Hysun Biomedical is planning to shift its health supplements manufacturing to India. Report

Suggested Articles

Gilead expects to sell 1 million to 1.5 million treatment courses of remdesivir in 2020. That means about $3.5 billion in sales, one analsyt figures.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Warp Speed's largest outlay to date, the funding will cover development and manufacturing scale-up of a vaccine that uses proven Sanofi technology.